Journal Article Summary
The article focuses on the development of a new formulation of loratadine, an antihistamine commonly used to treat allergies, in the form of nanoparticles. The significance of this study lies in addressing the challenges associated with loratadine's oral bioavailability, which can be affected by stomach acidity. By creating a gastro-resistant nanosuspension, the researchers aimed to enhance the drug's stability and effectiveness, potentially improving patient outcomes in allergy treatment.
To conduct the study, the researchers prepared loratadine-loaded nanoparticles using a method called solvent displacement evaporation, incorporating various polymers to create a protective coating. They evaluated the particle size, stability, and drug release profiles in simulated gastrointestinal fluids. The results showed that the nanoparticles had a small average size of about 46 nanometers and released 100% of the loratadine in intestinal conditions within 40 minutes, while less than 5% was released in stomach conditions. The formulation demonstrated good stability over three months, indicating its potential for practical use.
However, the study does have limitations, including the need for further research to confirm the long-term safety and efficacy of the nanoparticles in human subjects. Patients should discuss any new treatments or formulations with their healthcare professionals, especially if they are currently taking loratadine or other medications. Understanding how this new delivery system might interact with existing treatments is crucial for ensuring patient safety and optimizing therapeutic outcomes.
Medication Safety Note
This journal article summary is provided for educational purposes only and is not medical advice. Always consult a licensed healthcare professional before starting, stopping, or changing any medication.
Article Cited
- Rodriguez Amado Jesus Rafael, Prada Ariadna Lafourcade, Duarte Jonatas Lobato, Keita Hady, da Silva Heitor Rivero, Ferreira Adriana Maciel, Sosa Edgar Hernandez, Carvalho Jose Carlos Tavares. Development, stability and in vitro delivery profile of new loratadine-loaded nanoparticles. Saudi Pharmaceutical Journal : SPJ 2017. DOI: 10.1016/j.jsps.2017.07.008. PMID: 30166904. PMCID: PMC6111125.
Featured Pill Pals Product
Loratadine 10 mg --- 300 Count Bottle --- Generic For Claritin --- Major / Rugby
Loratadine 10 mg --- 300 Count Bottle --- Generic For Claritin --- Major Pharma is available through Pill Pals Pharmacy with cash-pay pharmacy pricing and free shipping where available. No prescription required for eligible over-the-counter purchases.
